Review
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. May 15, 2021; 12(5): 541-555
Published online May 15, 2021. doi: 10.4239/wjd.v12.i5.541
Recent advances in new-onset diabetes mellitus after kidney transplantation
Tess Montada-Atin, G V Ramesh Prasad
Tess Montada-Atin, G V Ramesh Prasad, Kidney Transplant Program, St. Michael's Hospital, Toronto M5C 2T2, Ontario, Canada
G V Ramesh Prasad, Department of Medicine, University of Toronto, Toronto M5C 2T2, Canada
Author contributions: Montada-Atin T critically reviewed and appraised the literature, and wrote the paper; Prasad GVR designed the study, critically reviewed and appraised the literature and wrote the paper; all authors read and approved the final manuscript.
Conflict-of-interest statement: Authors declare no conflict of interests for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: G V Ramesh Prasad, MBBS, PhD, Professor, Kidney Transplant Program, St. Michael's Hospital, 61 Queen Street East, 9th Floor, Toronto M5C 2T2, Ontario, Canada. ramesh.prasad@unityhealth.to
Received: January 27, 2021
Peer-review started: January 27, 2021
First decision: February 25, 2021
Revised: March 5, 2021
Accepted: April 14, 2021
Article in press: April 14, 2021
Published online: May 15, 2021
Processing time: 98 Days and 18.2 Hours
Core Tip

Core Tip: Kidney transplant recipients commonly develop post-transplant diabetes mellitus. Sodium glucose co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase 4 inhibitors are now available for treating type 2 diabetes mellitus. There is increasing evidence that these classes of drugs are effective in kidney transplant recipients, but caution is still advised due to their increased propensity otherwise for intravascular volume depletion, infections, and reduced kidney function.